STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences:
DNB Carnegie Healthcare Conference
Location: Stockholm, Sweden
Format: Presentation and 1×1 meetings
Presentation Date and Time: Thursday, March 12 at 9:10 AM CET
Participant: Mikael Nygård, COO
10th Annual Nordic-American Healthcare Conference
Location: New York, USA
Format: Presentation and 1×1 meetings
Presentation Date and Time: Wednesday, March 25 at 2:00 PM EST
Participant: Megan Richards, VP of IR and Comms
For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, [email protected]
Hans Jeppsson, CFO, +46 70 553 14 65, [email protected]
About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com
Attachments
Vicore Pharma to Present at Upcoming Investor Conferences
SOURCE: Vicore Pharma Holding
View the original press release on ACCESS Newswire